Injective's INJ token surged 23-28% in one day, reaching above $9.10, outpacing other layer-1 tokens like NEAR and Sei. The rally is driven by 21Shares' amended filing for an Injective ETF that would hold and stake INJ directly, aiming for a Nasdaq listing as TINJ. Other firms like Canary Capital and REX-Osprey are also pursuing staked INJ ETF filings, potentially locking up a large portion of tokens. Combined with a recent governance-approved supply contraction, this could tighten INJ's available supply and attract new investors if regulators approve the ETFs. Investors should watch regulatory responses, trading volume sustainability, and on-chain activity to gauge future momentum.
Injective's INJ token is up 16.77% on Pluang, trading at Rp160.476 as of Oct 16, 2026 22:21 WIB. Meanwhile, NEAR and SEI show smaller gains of 0.80% and 6.13% respectively, with NEAR at Rp91.165 and SEI at Rp1.167 on Pluang at the same time.
WLD leads the domestic crypto interest index in Korea with 85.6 points and accounts for 6.67% of local trading. XRP holds the largest domestic trading share among top assets at 13.98%, followed by NEAR and ONDO. STX shows the highest domestic trading...
Injective (INJ) surged 25.6% to $9.06, topping CoinMarketCap's global trending list as all top 10 tokens gained. Celestia (TIA) and Paimon Polymarket SPV Token also saw notable increases. In Korea, Zilliqa (ZIL) was the most viewed token but dropped ...
Injective (INJ) surged 24.29% to $9.11, leading a strong market rally where 81 of the top 90 cryptocurrencies, excluding stablecoins, advanced. Other notable gainers included LayerZero (ZRO) up 16.27%, Pyth Network (PYTH) up 14.96%, and Venice Token ...
Altcoins outperformed Bitcoin, with Celestia rising 16%, Injective up 7.7%, and LayerZero gaining 7.3%, while Bitcoin remained stable around $82,100. The Federal Reserve Chair Kevin Warsh gave no clear indication on upcoming interest rate decisions, ...
The Injective (INJ) token has risen over 30% following a breakout from a bullish cup-and-handle pattern, with analysts projecting a price target near $14. Injective leads major blockchains in revenue relative to fully diluted market cap, outperformin...
